Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Improves Survival of Patients with Peritoneal Carcinomatosis from Gastric Cancer: Final Results of a Phase III Randomized Clinical Trial by Yang, Xiao-Jun et al.
ORIGINAL ARTICLE – GASTROINTESTINAL ONCOLOGY
Cytoreductive Surgery and Hyperthermic Intraperitoneal
Chemotherapy Improves Survival of Patients with Peritoneal
Carcinomatosis from Gastric Cancer: Final Results of a Phase III
Randomized Clinical Trial
Xiao-Jun Yang, MD
1, Chao-Qun Huang, MD
1, Tao Suo, MD
2, Lie-Jun Mei, MD
1, Guo-Liang Yang, MD
1,
Fu-Lin Cheng, MD
1, Yun-Feng Zhou, MD, PhD
1, Bin Xiong, MD, PhD
1, Yutaka Yonemura, MD, PhD
3,
and Yan Li, MD, PhD
1
1Department of Oncology, Hubei Cancer Clinical Study Center and Hubei Key Laboratory of Tumor Biological Behaviors,
Zhongnan Hospital of Wuhan University, Wuhan, China;
2Department of General Surgery, Zhongshan Hospital of Fudan
University, Shanghai, China;
3NPO Organization to Support Peritoneal Dissemination Treatment, Kishiwada, Osaka, Japan
ABSTRACT
Background. This randomized phase III study was to
evaluate the efﬁcacy and safety of cytoreductive surgery
(CRS) plus hyperthermic intraperitoneal chemotherapy
(HIPEC) for the treatment of peritoneal carcinomatosis
(PC) from gastric cancer.
Methods. Sixty-eight gastric PC patients were randomized
into CRS alone (n = 34) or CRS ? HIPEC (n = 34)
receiving cisplatin 120 mg and mitomycin C 30 mg each in
6000 ml of normal saline at 43 ± 0.5C for 60–90 min.
The primary end point was overall survival, and the sec-
ondary end points were safety proﬁles.
Results. Major clinicopathological characteristics were
balanced between the 2 groups. The PC index was 2–36
(median 15) in the CRS ? HIPEC and 3–23 (median 15) in
the CRS groups (P = 0.489). The completeness of CRS
score (CC 0–1) was 58.8% (20 of 34) in the CRS and
58.8% (20 of 34) in the CRS ? HIPEC groups
(P = 1.000). At a median follow-up of 32 months
(7.5–83.5 months), death occurred in 33 of 34 (97.1%)
cases in the CRS group and 29 of 34 (85.3%) cases of the
CRS ? HIPEC group. The median survival was 6.5
months (95% conﬁdence interval 4.8–8.2 months) in
CRS and 11.0 months (95% conﬁdence interval 10.0–
11.9 months) in the CRS ? HIPEC groups (P = 0.046).
Four patients (11.7%) in the CRS group and 5 (14.7%)
patients in the CRS ? HIPEC group developed serious
adverse events (P = 0.839). Multivariate analysis found
CRS ? HIPEC, synchronous PC, CC 0–1, systemic che-
motherapy C 6 cycles, and no serious adverse events were
independent predictors for better survival.
Conclusions. For synchronous gastric PC, CRS ? HIPEC
with mitomycin C 30 mg and cisplatin 120 mg may
improve survival with acceptable morbidity.
Gastric cancer (GC) is a pathophysiologically hetero-
geneous disease, associated with predominantly lymphatic
spread, hematogenous metastasis or intra-abdominal
spread. For the lymphatic and hematogenous metastases,
reasonably extended lymphadenectomy, regional radio-
therapy, and adjuvant antitumor chemotherapy have been
proved effective, as demonstrated by several large scale
international studies such as INT-0116 trial, the MAGIC
trial, and the ACTS-GC trial.
1–3 These trials all show the
same pattern of cancer recurrence, that is either the patients
were treated by surgery alone or surgery plus peri- or
postoperative chemoradiotherapy, regional recurrence
(typically abdominal carcinomatosis) is the most common
pattern of ﬁrst recurrence.
These results reﬂect the fact that GC is a disease with
easy intra-abdominal spread, largely because free cancer
cells in peritoneal washings could be detected in up to 24%
of stage IB GC, and up to 40% of those with stage II or III
diseases.
4 In diffuse type GC, peritoneal seeding (recur-
rence) is a characteristic feature of cancer spread.
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of peritoneal recurrence.
6 In addition, established perito-
neal carcinomatosis (PC) is detected in more than 30% of
patients with advanced GC. Accordingly, almost 60% of all
causes of GC death is from PC.
7
PC from GC is characterized by the presence of tumor
nodules of various size, number and distribution on parietal
or/and visceral peritoneal surfaces, with very poor prog-
nosis and a median survival of less than 6 months.
8 As PC
is currently regarded as a variant of systemic spread of
disease, treatments for such patients are palliative systemic
chemotherapy and best support care, with limited efﬁcacy.
These nihilistic treatment approaches are ill conceived, as
data supporting systemic therapy for secondary PC is
derived from clinical trials reporting the results of treat-
ment of distinctively different tumor biology-visceral
metastasis of hematogenous origin, not PC.
9 To tackle this
problem, a more aggressive treatment strategy called
cytoreductive surgery (CRS) plus hyperthermic intraperi-
toneal chemotherapy (HIPEC) has been developed over the
past 3 decades, taking advantages of surgery to reduce
visible tumor burden, and regional hyperthermic chemo-
therapy to eradicate micro-metastases, expanding cancer
surgery from resection of primary tumor to surgical man-
agement of metastatic diseases.
10
Cohort studies suggested CRS plus HIPEC could
improve outcome of patients with PC from GC.
11–13 Non-
randomized comparative studies suggested the superior
efﬁcacy of CRS ? HIPEC over CRS alone forthe treatment
of gastric PC.
14,15 So far, however, only a few prospective
randomized clinical trials have been conducted to support
such treatment strategy, which is a major reason for skep-
ticism and criticism among the oncology community.
16,17
This phase III prospective randomized clinical trial was to
evaluate the efﬁcacy and safety of CRS plus HIPEC for PC
from GC.
PATIENTS AND METHODS
Patients
Sixty-eight gastric PC patients, including 35 men and 33
women, aged 24–75 years (median 50 years) were recrui-
ted onto this study. Before treatment, all patients had
signed informed consent, and the study protocol was
approved by the ethics committee of Zhongnan Hospital of
Wuhan University. These patients were randomized into
the CRS group and CRS ? HIPEC group according to a
computer-generated randomize number. Detailed study
information is available at ClinicalTrials.gov (http://www.
clinicaltrials.gov/ct2/show/NCT00454519). Routine pre-
operative studies included thorough physical examination,
blood test, serum biochemistry and electrolytes, liver and
renal function evaluation and coagulation studies. Other
examinations included chest x-ray, contrast-enhanced
three-dimensional abdominal-pelvic computed tomogra-
phy, and cardiac function assessments. Patient inclusion
criteria were: (1) age 20–75 years old; (2) Karnofsky per-
formance status of[50; (3) life expectancy of[8 weeks;
(4) normal peripheral blood white blood cells count
C3500/mm
3 and platelet count C80,000/mm
3; (5) accept-
able liver function, with bilirubin no greater than 2 times
the upper limit of normal (ULN), and aspartic amino-
transferase and alanine aminotransferase no greater than 2
ULN; (6) acceptable renal function, with serum creatinine
no greater than 1.5 mg/dl; and (7) cardiovascular pul-
monary and other major organ functions can stand major
operation. Major exclusion criteria were: (1) age\20 years
or[75 years; (2) any lung metastasis, liver metastasis, or
prominent retroperitoneal lymph node metastasis during
preoperative assessment; (3) serum bilirubin level [3
ULN; (4) liver enzymes[3 ULN; and (5) serum creatinine
level[1.5 mg/dl.
CRS and HIPEC
All CRS and HIPEC procedures were performed by a
designated team of surgical oncologists, anesthesiologist
and operating room staff, with the principal investigator
(Y.L.) as the chief surgeon. The abdominal exploration was
performed under general anesthesia and hemodynamic
monitoring, through a midline xiphoid-pubic incision.
Once the abdominal wall was open, detailed evaluation of
peritoneal carcinomatosis index (PCI) was conducted,
taking into consideration the size and distribution,
according to the principle of Sugarbaker.
18 We deﬁned
PCI\20 as low PCI and PCI C 20 as high PCI. The
characteristics of ascites were also recorded. After evalu-
ation, maximal CRS was performed, including the
resection of the primary tumor with acceptable margins,
any involved adjacent structures, lymphadenectomy, peri-
toneotomies where peritoneal surfaces were involved by
tumor, according to the peritonectomy procedure devel-
oped by Sugarbaker.
18
After surgery, HIPEC was performed before closure of
abdominal cavity, as this open technique is believed to
provide optimal thermal homogeneity and spatial diffusion,
with 120 mg of cisplatin and 30 mg of mitomycin C each
dissolved 6 l of heated saline (drug concentration cisplatin
20 lg/ml, mitomycin C 5 lg/ml).
19,20 An outﬂow tube
for perfusion was placed in Douglas’ pouch just before
HIPEC. The heated perfusion solution was infused into
the peritoneal cavity at a rate of 500 ml/min through the
inﬂow tube introduced from an automatic hyperthermia
1576 X.-J. Yang et al.chemotherapy perfusion device (ES-6001, Wuhan E-sea
Digital Engineering, Wuhan, China). The skin of the
abdomen is attached to a retractor ring and a plastic sheet
covered the open wound to keep the temperature stable.
The perfusion in the peritoneal cavity was stirred manually
with care not to infuse directly on the bowel surface. The
temperature of the perfusion solution in peritoneal space
was kept at 43.0 ± 0.5C and monitored with a ther-
mometer on real time. The total HIPEC time was
60–90 min, after which the perfusion solution in the
abdominal cavity was removed through the suction tube,
and drainage tubes were placed at appropriate sites
depending on the type of primary operation. The wound
was closed with relaxing suture, and patient was delivered
to the intensive care unit for recovery. When the condition
stabilized, usually 24–48 h later, the patients were trans-
ferred to the surgical oncology ward.
The extent of CRS was determined by Sugarbaker’s
criteria on the completeness of cytoreduction (CC).
18,21 A
score of CC-0 indicates no residual peritoneal disease after
CRS; CC-1, less than 2.5 mm of residual disease; CC-2,
residual tumor between 2.5 mm and 2.5 cm; and CC-3,
more than 2.5 cm of residual tumor or the presence of a
sheet of unresectable tumor nodules.
The primary end point was disease speciﬁc overall
survival (OS), deﬁned as time interval from randomization
to death due to disease. The secondary end points were
serious adverse events (SAE), deﬁned as severe local and/
or systemic infection, abdominal leakage, or death related
to the procedure.
Statistical Analysis
All patients were regularly followed up for detailed
monitoring of disease status. Data were obtained from a
database of clinical records, surgical reports, medical
imaging reports, laboratory and pathology reports, and
follow-up records. Patients alive at the time of analysis
were censored at the last follow-up. OS was estimated by
the Kaplan–Meier method, stratiﬁed by PCI and CC, and
tested with the log-rank test.
This trial was designed to detect a 30% absolute dif-
ference in OS. With a statistical power of 90% to detect
such difference and 5% signiﬁcance level, at least 60
patients had to be entered. Categorized variables in the two
groups were compared by chi square test or Fisher’s exact
test. The numerical data were directly recorded, and the
category data were recorded into different categories. The
Kaplan–Meier method was used to compare the survival,
with log rank test. Data were analyzed by the Statistical
Package for Social Sciences (SPSS, Chicago, IL), version
13.0, with a 2-sided P value of \0.05 considered statisti-
cally signiﬁcant.
RESULTS
Baseline Data and Surgical Intervention
A total of 68 patients were randomized into CRS alone
(n = 34) and CRS ? HIPEC (n = 34) groups. These
patients were well balanced and comparable regarding
major baseline clinicopathological characteristics and sur-
gical procedures (Table 1).
Survival Analysis
At the time of this writing, the median follow-up was
32 months (7.5–83.5 months). Disease speciﬁc death had
occurred in 33 of 34 (97.1%) cases in the CRS group and
29 of 34 (85.3%) cases in the CRS ? HIPEC group. Fol-
low-up, therefore, is long enough to demonstrate any
impact of this new therapy on survival, and the data are
mature for ﬁnal analysis.
The median OS was 6.5 months (95% conﬁdence
interval [CI] 4.8–8.2 months) in CRS group and 11.0
months (95% CI 10.0–11.9 months) in the CRS ? HIPEC
group (P = 0.046, log rank test) (Fig. 1a). The 1-, 2-, and
3-year survival rates were 29.4, 5.9 and 0% for CRS group,
and 41.2, 14.7 and 5.9% for CRS ? HIPEC group.
In patients with synchronous PC (n = 51), the median
OS was 12.0 months (95% CI 8.1–15.9 months) in
CRS ? HIPEC group (n = 24) and 6.5 months (95% CI
5.0–8.0 months) in the CRS group (n = 27) (P = 0.029)
(Fig. 1b).
There were 17 patients with metachronous PC, including
10 in the CRS ? HIPEC group and 7 in the CRS alone
group. The number was too small for any deﬁnite conclu-
sion, although the median OS was shorter in the
CRS ? HIPEC group (5.5 months) than in the CRS alone
group (11.0 months).
We further investigated the impact of CC on survival. In
the CRS ? HIPEC group, the median OS was 12.0 months
(95% CI 8.1–16.0 months) in CC 0–1 subgroup (n = 20)
and 8.2 months (95% CI 0.5–16.5 months) in CC 2–3
subgroup (n = 14) (P = 0.000) (Fig. 2a). In CRS group,
the median OS was 11.0 months (95% CI 8.8–13.2
months) in CC 0–1 subgroup (n = 20) and 4.0 months
(95% CI 1.3–6.8 months) in CC 2–3 subgroup (n = 14)
(P = 0.000) (Fig. 2b). In patients with incomplete cytore-
duction, HIPEC ? CRS brought longer OS than CRS alone
(median OS 8.2 vs. 4.0 months, P = 0.024).
The impact of PCI on survival was also analyzed. In the
high PCI group (n = 23), the median OS was 13.5 months
CRS ? HIPEC for Gastric Peritoneal Carcinomatosis 1577(95% CI 8.7–18.3 months) in CRS ? HIPEC subgroup
(n = 14), and 3.0 months (95% CI 2.4–3.6 months) in
CRS subgroup (n = 9) (P = 0.012, log-rank test). In the
low PCI group (n = 45), the median OS was 10.2 months
(95% CI 9.3–11.1 months) in CRS ? HIPEC subgroup
(n = 20), and 10.5 months (95% CI 4.0–17.0 months) in
CRS subgroup (n = 25) (P = 0.464, log-rank test).
Multivariate analysis by Cox regression model identiﬁed
CRS ? HIPEC, synchronous PC, CC 0–1, systemic che-
motherapy [6 cycles, and no SAE as major independent
predictors for better survival, while age, sex and PCI were
not independent survival factors (Table 2). Compared
with CRS alone, CRS ? HIPEC is about 2.6 times likely
to improve survival (hazard ratio = 2.617; 95% CI 1.436–
4.769).
Adverse Events
SAE had occurred in 9 patients, 4 in the CRS group
(11.7%) and 5 in the CRS ? HIPEC group (14.7%) (P =
0.839). These SAE included wound infection and sepsis,
respiratory failure, gastrointestinal bleeding, severe bone
marrow suppression, and intestinal obstruction (Table 3).
SAE had a marked negative impact on survival. The median
OS of patients who developed SAE was 5.0 months in CRS
groupand3.0 monthsintheCRS ? HIPECgroup,although
the number was too small for deﬁnite statistical analysis.
Patterns of Treatment Failure
Disease speciﬁc death had occurred in 33 of 34
(97.1%) cases in the CRS group and 29 of 34 (85.3%)
cases of the CRS ? HIPEC group. Among the 29 deaths
in the CRS ? HIPEC group, 1 was due to massive
mediastinal lymph nodes and brain metastases leading to
intracranial hemorrhage after radiotherapy, 1 was due to
respiratory failure, and the remaining 27 were due to
abdominal recurrence leading to progressive intestinal
obstruction. Among the 33 deaths in the CRS group, 1
was due to widespread bone metastasis leading to bone
marrow failure, 1 was due to massive systemic metas-
tases involving the lungs, the liver, and the brain, 2 due
to respiratory failure, and the remaining 27 were due to
abdominal obstruction secondary to PC recurrence or
progression.
DISCUSSION
There is no standard treatment for PC from GC. CRS
plus HIPEC represent a multidisciplinary approach to this
TABLE 1 Clinicopathological characteristics of 68 patients with
peritoneal carcinomatosis
Variable With
HIPEC
(N = 34)
CRS alone
(N = 34)
P value
Age (years)
Median (range) 50 (24–74) 51 (28–75) NS
Gender (n)
Male/female 16/18 19/15 NS
PCI
Range 2–36 3–23 NS
Median 15 15
PCI[20 14 (41.2%) 9 (26.5%) 0.206
(NS)
Histological diagnosis
Well/intermediately
differentiated
adenocarcinoma
10 (29.4%) 6 (17.8%) NS
Poorly/undifferentiated
adenocarcinoma
19 (55.9%) 24 (70.4%)
Signet ring cell carcinoma 4 (11.8%) 0 (0.0%)
Mucous carcinoma 0 (0.0%) 2 (5.9%)
Squamous-cell carcinoma 1 (2.9%) 2 (5.9%)
Organ resections
Total gastrectomy 8 3 NS
Subtotal gastrectomy 25 31
Splenectomy 2 1
Ovariectomy 12 5
Colectomy 0 2
Partial hepatectomy 1 0
Peritonectomy locations
Right diaphragmatic copula 10 7 NS
Left diaphragmatic copula 15 16
Greater omentum 34 34
Lesser omentum 34 34
Omental bursa 34 34
Right colon gutter 15 16
Left colon gutter 20 21
Douglas pouch 20 14
Anterior wall peritoneum 15 10
Mesenteric fulguration 23 9
CC 0–1 20/34
(58.8%)
20/34
(58.8%)
Median blood loss during
operation, ml (range)
800
(500–3000) 600
(400–1200) NS
Median operating time
(excluding HIPEC),
h (range)
5.0
(4.0–7.5)
4.0
(3.0–5.5)
NS
CC Completeness of cytoreduction, NS not signiﬁcant
1578 X.-J. Yang et al.problem. It was ﬁrst reported in 1988 by Fujimoto et al on
15 patients with PC secondary to advanced GC, with
a mean survival of 7.2 ± 4.6 months with acceptable
morbidity.
22 This new treatment modality gradually gains
acceptance in many countries. Although the reported
studies use different PCI scoring system to evaluate the
extent of PC and different HIPEC approaches, they pro-
duce similar results that CRS plus HIPEC is an appropriate
AB FIG. 1 CRS ? HIPEC
provides far better survival
advantage than the CRS alone
group in patients with gastric
PC (a), particularly in patients
with synchronous gastric PC (b)
AB FIG. 2 In either
CRS ? HIPEC group (a)o r
CRS alone group (b), patients
with CC 0–1 cytoreduction had
better survival advantage
TABLE 2 Multivariate analysis on factors inﬂuencing survival
Covariate v
2 P value Hazard ratio 95% CI
Sex (M vs. F) 0.099 0.753 1.101 0.605–2.002
Age (\60 years vs. C60 years) 0.638 0.425 1.275 0.702–2.317
PCI (low PCI vs. high PCI) 0.292 0.589 1.222 0.590–2.529
Treatment (CRS ? HIPEC vs. CRS alone) 9.871 0.002 2.617 1.436–4.769
PC state (synchronous vs. metachronous) 5.438 0.02 2.228 1.136–4.367
CC (0–1 vs. 2–3) 8.585 0.003 2.794 1.405–5.556
Chemotherapy (C6 vs.\6 cycles) 15.649 0 3.344 1.838–6.061
SAE (no vs. yes) 13.765 0 4.295 1.989–9.274
PCI Peritoneal carcinomatosis index, CRS cytoreductive surgery, HIPEC hyperthermic intraperitoneal chemotherapy, PC peritoneal carcino-
matosis, CC completeness of cytoreduction, SAE serious adverse events
CRS ? HIPEC for Gastric Peritoneal Carcinomatosis 1579treatment option for a selected subgroup of GC patients
with PC, and for advanced GC with high risk of developing
PC. A systematic review and meta-analysis of 13 accept-
able quality randomized controlled trials also have
established that HIPEC is associated with marked
improvement in survival in advanced GC, in comparison
with the current standard treatments.
17 As a result, a panel
of international experts strongly recommend that CRS plus
HIPEC be the current standard treatment for advanced
GC.
23 Nevertheless, controversy over this treatment
modality remains, and more high quality clinical studies
are required to clarify the value and the usefulness of this
strategy.
In this prospective randomized study, CRS and HIPEC
has been demonstrated to provide survival beneﬁt for gas-
tric PC. The median OS was 6.5 months for CRS group and
11.0 months for CRS ? HIPEC group. The results were
similar to those reported by Glehen et al. (OS 10.3 months)
and Yonemura et al. (OS 11.5 months).
13,24 Compared with
CRS alone, CRS ? HIPEC could extend the OS by nearly
70% (6.5 vs. 11.0 months). This is similar to the 76%
improvement of OS (22.2 vs. 12.6 months) favoring
CRS ? HIPEC in the landmark phase III clinical trial in
colorectal PC by the Netherlands Cancer Institute, which
has provided level 1 evidence to support HIPEC with CRS
for colorectal PC.
16 Taking together, these results suggest
that in either gastric or colorectal PC, CRS ? HIPEC could
provide similar survival advantage in selected cases.
Our results also demonstrated that patients with
metachronous PC had worse survival than those with
synchronous PC, in agreement with Glehen et al.
13 The
usefulness of CRS ? HIPEC was evident for synchronous
PC (median OS 12.0 vs. 6.5 months). For metachronous
PC, the number was too small for any deﬁnite conclusion,
although the median OS was shorter in the CRS ? HIPEC
group (5.5 months) than in the CRS alone group
(11.0 months). More studies with greater sample size are
required to clarify this issue.
This study demonstrated again the importance of com-
plete cytoreduction for long term survival. Whether
patients underwent CRS alone or CRS ? HIPEC, CC 0–1
was independently associated with longer survival (Fig. 2).
Therefore, efforts should be focused on complete CRS.
The synergistic effects of CRS to remove the macro-
scopic tumor and HIPEC to eradicate microscopic residual
diseases are major advantages of this combined approach.
However, such a procedure also brings greater risks for
major morbidity and mortality. Major complications are
directly related to the magnitude of the procedure,
including the extent of resections and peritonectomy, the
number of anastomoses, the duration of surgery, and the
doses of cytotoxic chemotherapeutic drugs used in
HIPEC.
25Asaresultofextensiveresection,morebloodloss,
and more complex gastrointestinal reconstruction, compli-
cations become more frequent. To minimize potential
complications, all patients in our group required blood,
plasma and cryoprecipitation transfusion and large doses of
antibiotics during and after operation. All patients were in
intensive care for at least 24 h after the procedure. Even in
intensiﬁed medical and surgical care, complications did
occur.IntermsofSAE,therewerenostatisticallysigniﬁcant
differences in the incidence of SAE between CRS group
(11.7%) and CRS ? HIPEC group (14.7%). But the
CRS ? HIPEC group had 3 cases with wound infection and
sepsis,possiblyasaresultoflongwoundexposureduringthe
lengthy operation. Our results are similar to the 19% grade
IV complication rate reported by Sugarbaker et al.
26
Our multivariate analysis demonstrated that SAE was an
independent factor for worse survival. Therefore, greater
efforts should be made to minimize SAE.
Severe hematological adverse events were not encoun-
tered in our patients. This could be due to relatively lower
doses of mitomycin C and cisplatin used. Although we did
not conduct pharmacokinetics studies to monitor the drug
metabolism in the perfusion ﬂuid, mitomycin C concen-
tration of 5 lg/ml (30 mg/6000 ml) is still above the
cytotoxic concentration, because previous studies have
conﬁrmed that 3 lg/ml of mitomycin C in HIPEC for 2 h
can kill all GC cells in ascites and on the peritoneal
surface.
27
In conclusion, this study has found that for synchronous
gastric PC, CRS ? HIPEC with mitomycin C 30 mg and
cisplatin 120 mg may improve survival with acceptable
morbidity.
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